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ABSTRACT 
Angiogenesis, the process of sprouting new microvessels from the pre-existing 
vasculature, is known to promote tumor growth. However, the role of tumor angiogenic 
vessels in facilitating metastasis remains poorly understood. In addition to 
hemangiogenesis, various types of tumors often contain lymphatic vessels, which may 
facilitate lymphatic metastasis. Cancer metastasis employs complex processes that are 
collectively termed as the metastatic cascade, which involves multiple-step defined 
mechanisms. A clinical detectable metastatic mass represents the ultimate consequence 
of the complex metastatic cascade that includes dissemination of tumor cell from the 
primary site; intravasion of tumor cells into the circulation or lymphatic system; 
transport of tumor cells along blood circulation or lymphatic system to distal tissues or 
organs; extravasation of tumor cells from the circulation of lymphatic system; 
formation of the primary metastatic niche in distal tissues; manipulation of metastatic 
microenvironment; and regrowth of metastatic nodules to a visible metastatic mass. 
Although advances of imagine techniques allows detection of relative small sizes of 
tumors in cancer patients and in experimental animal models, the early onset of 
metastatic processes remains unknown. As for lymphangiogenesis, there has been 
lacking appropriate and powerful in vivo assay systems that allow quantitatively study 
lymphangiogenesis. In this thesis work, we have: 1) developed a novel zebrafish model 
to study the early steps of the metastatic cascade.  We take the advantage of the 
transparent nature of zebrafish embryos to visualize under normoxic and hypoxic 
conditions marked human or mouse tumor cell migration and invasion in association 
with tumor angiogenesis. We have found that tumor angiogenesis is essentially 
required for tumor cell invasion and dissemination. This study, for the first time, 
provides compelling evidence of tumor cell-tumor vessel interaction in promoting 
cancer cell dissemination to distal sites; 2) studied the interplay between FGF-2 and 
VEGF-C in promoting lymphatic metastasis. In the tumor microenvironment, various 
angiogenic factors often co-exist and they often cross-communicate with different 
signaling pathways. Although the individual factor-transduced vertical signals via their 
specific receptors are relatively well studied, their horizontal interplay with other 
signaling systems remains poorly characterized. We show that FGF-2-triggered 
lymphangiogenic signaling pathways synergistically promote lymphangiogenesis with 
the VEGF-C-VEGFR-3 system, leading to synergistic lymphangiogenic effects in 
various in vivo models. A clear lymphangiogenic synergism between FGF-2 and 
VEGF-C has been observed in the tumor microenvironment. Importantly, this 
synergistic lymphangiogenic activity leads to accelerated lymphatic metastasis in 
sentinel lymph nodes; 3) developed a unique in vivo model to study lymphangiogenesis 
induced by various factors. We take the advantage of the avascular nature of the mouse 
corneal tissue and implant various growth factors/cytokines alone or in combinations to 
quantitatively study lymphangiogenesis and lymphatic structures; and 4) studied the 
impact of clinical available antiangiogenic drugs on healthy vasculature and revealed 
potential sites for antiangiogenic drug-related side effects. 
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1 INTRODUCTION 
 
1.1 ANGIOGENESIS 
 
Angiogenesis, the process of sprouting new microvessels from the pre-existing, has 
been recognized since 1971 by Dr. Judah Folkman who proposed that tumor growth 
is angiogenesis dependent1. Today, it is well established that tumor growth and 
metastasis are dependent on the development of new blood vessels and lymphatic 
vessels.  
 
Sprouting angiogenesis occurs in several well-characterized stages: Angiogenic 
growth factors activate their cognate receptors present on endothelial cells (ECs) of 
pre-existing blood vessels; The activated ECs begin to release enzymes called 
proteases that degrade the basement membrane; ECs change morphology, proliferate, 
migrate and adhere tightly in tandem using adhesion molecules to form the new 
vessel wall of sprouts; The sprouts finally become a full-fledged vessel lumen to 
establish network of capillaries. Newly formed capillary sprouts are fragile. The 
supporting cells including pericytes for small capillaries and vascular smooth muscle 
cells (vSMCs) for larger vessels proliferate and migrate in parallel to the growth of 
the vascular sprout to solidify and stabilize the newly formed sprouts1-4. 
 
Angiogenesis is a complex balance process regulated by angiogenic factors and 
inhibitors5-7. The activation of angiogenesis requires up-regulation of angiogenic 
factors and/or down-regulation of endogenous inhibitors7-10. These angiogenic or 
anti-angiogenic factors may arise from various sources such as ECs, stromal cells, 
inflammatory cells, cancer cells or hypoxia. There are many angiogenic factors, such 
as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), etc2,11. 
Although the list of angiogenic stimulators is constantly growing, VEGF family is the 
best characterized regulators of angiogenesis. VEGF is one of the key angiogenic 
factors that contributes to the onset and progression of many pathological conditions 
including cancers12. 
 
Hypoxia induces a complex response in a tissue, which aims at protecting the cells 
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against and counteracting the loss of oxygen. Sprouting angiogenesis is initiated in 
poorly perfused tissues when hypoxia in the tissue demands the formation of new 
blood vessels to satisfy the metabolic requirements of parenchymal cells (myocytes, 
hepatocytes, neurons, astrocytes, etc). Parenchymal cells respond to a hypoxic 
environment by secreting VEGF-A13. Hypoxia triggers an angiogenic response via 
the hypoxia inducible factor (HIF) 1-α- VEGF pathway13-16.  
 
 
1.1.1 Angiogenic stimulators 
 
1.1.1.1 Vascular endothelial growth factor family 
 
As we may know, VEGF family contains six structurally related growth factors, 
including VEGF-A, -B, -C, -D, -E, and placental growth factors (PlGF)6. The 
angiogenic activities of VEGF family are mediated through two structurally related 
tyrosine kinase receptors mainly expressed in ECs, VEGFR-1 and VEGFR-217-21. 
Abundant experimental data demonstrate that VEGFR-2 is the primary functional 
receptor that transduces both angiogenic and vascular permeability signals, whereas 
VEGFR-1 may function as a decoy receptor22,23.  
 
In addition to VEGFR-1 and VEGFR-2, VEGFR-3, a lymphatic endothelial cell 
specific tyrosin kinase receptor, has been identified24-27. VEGF-C and VEGF-D can 
activate VEGFR-3 to induce lymphangiogenesis28,29. In addition to tyrosine kinase 
receptors, VEGF isoforms can interact with neuropilin-1 and -2, which serve as co-
receptors of the VEGFR-1, VEGFR-2 and VEGFR-3 to modulate angiogenesis and 
lymphangiogenesis22. VEGFs and VEGF receptors signaling pathways are critical for 
inducing angiogenesis and lymphangiogenesis in physiological and pathological 
situations30,31. 
 
VEGF-A is an abundant endothelium-specific growth factor. It can stimulate 
proliferation, migration, sprouting and tube formation of ECs, as well as vascular 
integrity32. Moreover, VEGF-A has been reported to act as a chemoattractant for 
vSMCs, implicating a role for VEGF-A in blood vessel stabilization5,33 VEGF-A is 
expressed in a wide variety of cell types, including embryonic fibroblasts, vSMCs, 
activated macrophages, keratinocytes and hepatocytes 20. 
   3 
 
The expression of VEGF-A is markedly up-regulated in hypoxic conditions via HIF1-
α/VEGF pathway13-16. VEGF transcription is activated and up-regulated in hypoxic 
condition27,34. 
 
PlGF was defined as an endothelial growth factor based on its sequence homology to 
VEGF. PlGF exclusively binds to VEGFR-1, which may function as a decoy receptor 
in regulation of VEGF-induced angiogenesis35,36. Although the direct role of PlGF still 
remains unknown under pathological conditions, PlGF has been shown to enhance 
VEGF-A-induced angiogenesis in part through a cross-talk between VEGFR-1 and 
VEGFR-235,36. PIGF has been suggested to indirectly stimulate angiogenesis by 
binding VEGFR-1, thereby increasing the fraction of VEGF-A molecules available to 
activate VEGFR-237.  
 
       
      Figure 1. The VEGF family (adapted from reference 22) 
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VEGF-B is reported to be expressed in developing heart and skeletal muscles38,39. 
VEGF-E, a non-mammalian viral protein, is a selective agonist for VEGFR-240. The 
precise physiological functions of VEGF-B and VEGF-E in vivo are still 
unknown41,42. In contrast to VEGF-A, VEGF-B plays a less pronounced role in 
angiogenesis. VEGF-B seems to bind to VEGFR-1 to play a role only in the 
maintenance of newly formed blood vessels under pathological conditions39,43,44  
 
VEGF-C and VEGF-D can activate VEGFR-3 to induce lymphangiogenesis. Recent 
studies have shown that VEGF-C/ VEGF-D/ VEGFR-3-mediated signals are critical in 
the sprouting of the first lymphatic vessel from the developing veins in the embryo, 
suggesting that this signalling pathway is essential for differentiation of endothelial 
progenitor cells into the lymphatic lineage24,42,45-49. In addition to activating VEGFR-3, 
VEGF-C and VEGF-D also activate VEGFR-2 and induce angiogenesis24,42,45-49. 
VEGF-C and VEGF-D will be discussed further in details in the lymphangiogenic 
section (page10-12). In addition to VEGF-C and VEGF-D, VEGF-A has also been 
shown to act as a potent lymphangiogenic factor. 
 
 
1.1.1.2 Fibroblast growth factor family 
 
Fibroblast growth factors are involved in angiogenesis, wound healing and embryonic 
development. In humans, more than twenty members of the FGF family have been 
identified50-52. All FGFs are structurally related signaling molecules. FGF-1 and FGF-
2 have been shown to promote angiogenesis, including ECs differentiation, 
proliferation, migration, integrin and cadherin receptor expression24,53. There are five 
fibroblast growth factor receptors: FGFR-1, -2, -3, -4, and FGFR-554,55. FGFs bind to 
four structurally related tyrosine kinase receptors FGFR-1, -2, -3, -4, which present 
on many different cell types, including ECs24,46,51,54,56-58. The fifth receptor, FGFR-5, 
lacks intracellular tyrosine kinase domain, and its role is less understood54,55,58.  
 
During embryonic development, the expression patterns of the FGF receptors are 
distinct but overlapping. FGFs/FGFR-1 signalling is reported to play an important 
role in the development and maintenance of vascular network in the 
embryo24,46,51,54,56-58. FGFR-1 mutant mouse embryos are developmentally retarded or 
even die during gastrulation stage. In recent years, the existence of intimate cross-
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talks between FGF-2 and members of the VEGF family, such as VEGF-C, during 
angiogenesis and lymphangiogenesis has been reported59. FGF-2 appears to induce 
angiogenesis by increasing VEGF expression in the ECs of forming capillaries60,61. 
 
FGF/FGFR signaling pathway plays an important role in normal organ, skeletal 
development and vascular formation. De-regulation of the FGF/FGFR signaling 
pathway through genetic modifications or overexpression of the receptors has been 
associated with many developmental disorders and promotion of disease progression, 
including induction of angiogenesis and lymphangiogenesis in cancers24,46,51,54,56-58. 
 
 
1.1.1.3 Other stimulators 
 
Angiopoietins (Ang) bind to the Tie receptors expressing within the vascular 
endothelium to regulate blood vessel formation62. Tie receptors include Tie-1 and 
Tie-2, which play a critical role in embryonic development. Ang-1 is a Tie-2 agonist. 
During the early stage of vascular development, Ang-1 promotes subsequent vascular 
remodeling and stabilization after the vascular formation63. The actions of Ang-2 are 
complex. Ang-2 appears to play critical roles in vascular remodeling, vessel sprouting, 
and vessel regression64. 
 
The Insulin-like growth factor family (IGF) consists of two ligands, IGF-1 and IGF-2. 
IGF-1 and IGF-2 bind to two transmembrane receptors, IGF-1R and IGF-2R65-67. 
IGF-1 binds to IGF-1R expressed on ECs to directly stimulate ECs proliferation, 
migration and tubule formation. IGF-1/ IGF-1R signaling pathway has been shown to 
modulate angiogenesis by stimulating the production of VEGF-A65-67. 
 
There are four ligands (PDGF-A, -B, -C, -D) in PDGF family, and two receptor 
subtypes, PDGFR-α and PDGFR-β. PDGF-A and PDGF-B monomers can dimerize 
with each other to form functional dimers. PDGF-BB is mostly expressed on vascular 
endothelium, whereas PDGFR-β is mainly expressed in pericytes, vSMCs, and 
mesenchyme surrounding blood vessels. PDGFs may play an important role in 
regulating angiogenesis. Recent studies have provided experimental evidence for the 
role of PDGFs in tumor angiogenesis and metastasis. It has been reported that FGF2 
and PDGF-BB can synergistically promote murine tumor neovascularization and 
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metastasis59,68,69.  
 
 
1.1.2 Angiogenic inhibitors 
 
1.1.2.1 Bevacizumab 
 
Bevacizumab (trade name Avastin) is a humanized VEGF neutralizing monoclonal 
antibody that has been widely used for treatment of various human cancers, including 
ovarian, lung, renal cell carcinoma (RCC) and glioblastoma70-77. Bevacizumab is the 
first clinically available angiogenesis inhibitor in the United States. Its main action is to 
inhibit the function of VEGF in angiogenesis. Bevacizumab binds directly to VEGF to 
form a protein complex of bevacizumab/VEGF complex to reduce available VEGF 
which is capable of further binding to VEGF receptor sites.  
 
 
1.1.2.2 Ramucirumab  
 
Ramucirumab is a fully humanized anti-human VEGFR-2 neutralizing monoclonal 
antibody being developed for the treatment of solid tumors. Ramucirumab directly 
binds to VEGFR-2 to work as a receptor antagonist blocking the binding of VEGF to 
VEGFR-2. Ramucirumab is being tested in several phase III clinical trials for the 
treatment of metastatic gastric adenocarcinoma, breast cancer and non-small cell lung 
carcinoma18,78,79.   
 
 
1.1.2.3 Sunitinib  
 
Sunitinib is a small-molecule and multi-targeted receptor tyrosine kinase (RTK) 
inhibitor that is approved by the FDA for the treatment of solid tumors, including 
RCC and gastrointestinal stromal tumor. Sunitinib inhibits cellular signaling by 
targeting RTKs, including VEGFRs, to inhibit both tumor angiogenesis and tumor 
cell proliferation80. 
 
 
   7 
1.1.3 Hypoxia and angiogenesis 
 
Oxygen availability is very important because most mammalian cells rely on aerobic 
metabolism to sustain energy production. Hypoxia is an effective driving force for 
angiogenesis, which represents a compensable mechanism against tissue ischemia. 
Sprouting angiogenesis is initiated in poorly perfused tissues when hypoxia in the 
tissue demands the formation of new blood vessels to satisfy the metabolic 
requirements of parenchymal cells. Hypoxia often triggers an angiogenic response 
mostly via the HIF signaling pathway. In hypoxic conditions, HIF prolyl-hydroxylase 
is inhibited and HIF1-α is stabilized, thus VEGF transcription is activated and up-
regulated81.  
 
The HIF family comprises HIF1-α, HIF2-α, HIF3-α and HIF1-β or ARNT124. HIF1-
α is important for acute responses to hypoxia. In clinics, many tumors are constantly 
hypoxic due to poorly perfused and low quality blood vessels because tumors express 
high levels of VEGF that significantly contributes to high degrees of leakiness and 
tortuosity of the tumor vasculature. Tumor hypoxia plays an important role in tumor 
cell dissemination and distant metastasis. However, the molecular mechanisms and 
detailed processes underlying hypoxia-associated metastasis remain poorly 
understood13-16,82-84.  
 
 
1.2 LYMPHANGIOGENESIS 
 
Lymphangiogenesis is the process of the growth of lymphatic vessels. Whereas the 
mechanisms of angiogenesis have been studied extensively, relatively little is known 
about the molecular mechanisms regulating lymphangiogenesis. The research on 
lymphangiogenesis was limited maybe due to the lack of immunohistochemical, 
accurate and specific markers to detect lymphatic endothelial cells (LECs). This 
limitation was improved recently with the identification of novel markers specifically 
expressed on LECs, such as VEGFR-3, lymphatic vessel endothelial hyaluronan 
receptor-1 (LYVE-1), prospero related homebox gene-1 (Prox-1) and podoplanin85-89.  
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1.2.1 Specific markers of lymphatic vessels 
 
1.2.1.1 Vascular endothelial growth factor receptor-3 
 
VEGFR-3 was the first specific marker for lymphatic vessels in both normal and 
pathological tissues including tumors. VEGFR-3 is activated by VEGF-C and VEGF-
D, both members of the VEGF family28,48. In adults, VEGFR-3 is expressed on the 
inner surface of lymphatic vessels. However, VEGFR-3 is also expressed in 
embryonic blood vascular endothelium. The expression of VEGFR-3 is up-regulated 
in blood vessels during pathological conditions, including inflammation, wound 
healing and tumor growth90. VEGFR-3 is still expressed in other tissues, such as 
endocrine glands, monocytes, macrophages and dendritic cells. 
 
 
1.2.1.2 Lymphatic vessel endothelial hyaluronan receptor-1 
 
LYVE-1, a CD44 homolog, is expressed in a subset of ECs in the large central veins 
and currently provides the first indicator of lymphatic endothelial competence. 
LYVE-1 is one of the most specific and widely used lymphatic endothelial 
markers91,92. The expression of LYVE-1 is largely restricted to lymphatic 
endothelium. LYVE-1 is expressed on both the lumenal and ablumenal surfaces of 
lymphatic endothelium, and also on hepatic blood sinusoidal endothelia. Potential 
roles of LYVE-1 have been suggested in hyaluronan (HA) transport and turnover, or 
in promoting HA localization to the surfaces of lymphatic endothelium. HA is a key 
mediator of cell migration during embryonic development. It is also important in 
adult processes such as wound healing and tumor metastasis93. However, further 
studies are required to explore the function of LYVE-1 in HA-transport and tumor 
metastasis. 
 
 
1.2.1.3 Prospero related homebox gene-1 
 
Prox-1 is specific for lymphatic vessels in the vascular system. Although Prox-1 was 
also found expressed in non-endothelial cells of the heart, liver and nervous system, 
the expression of Prox-1 persists in adult lymphatic endothelium94. Prox-1 has been 
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reported to be a transcription factor involved in the budding and elongation of 
lymphatic vessels sprouts89,95. 
 
 
1.2.1.4 Podoplanin 
 
Podoplanin is a glomerular podocyte membrane mucoprotein required for lymphatic 
development96,97. Podoplanin is expressed strictly in lymphatic endothelium, but not 
in the blood vasculature98. In the lymphatic system, podoplanin is expressed in small 
lymphatic capillaries lined by a single layer of LECs. Podoplanin knockout mice have 
defects in lymphatic vessel and die at birth due to respiratory failure99.  
 
 
1.2.2 Functions of the lymphatic vascular system 
 
The lymphatic vascular system comprises a tree-like hierarchy of capillaries, 
collecting lymphtic vessels, and the right and left ducts100. Lymphatic capillaries are 
blind ended, irregularly shaped, and larger in diameter than blood capillaries, lined by 
a single layer of non-fenestrated LECs101. Unlike blood capillary endothelium, LECs 
have poorly developed junctions with large frequent inter-endothelial gaps. LECs 
lack continuous basement membranes, and adjacent cells lack junctions and instead 
overlap at their edges. Lymphatic capillaries harbour discontinuous or completely 
absent basement membranes, and are not invested by pericytes or vSMCs. The 
abluminal surfaces of LECs are attached to the extracellular matrix via elastic 
anchoring fibers. These elastic anchoring fibers keep the lymphatic vessels from 
collapsing and also promote their dilation to allow the flow of interstitial fluid to the 
lymphatics102.  
 
The lymphatic capillaries are responsible for the uptake of lymph, which consists of 
interstitial fluid, macromolecules and cells. The physiological function of lymphatic 
vascular system is to drain excess fluid, and then transport them to the blood vessels 
for circulation. When fluid accumulates and interstitial pressure increases, the 
anchoring fibers separate the LECs, generating gaps between adjacent cells and 
allowing for fluid drainage into the lymphatic vessel. From the capillaries, the lymph 
is transported to the collecting lymphatics, then ultimately into the venous circulation 
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via the thoracic duct103-105. 
 
The lymphatic system is also concerned with immune functions by filtering lymph 
through a chain of lymph nodes before entering the venous circulation. Lymph nodes 
are located at intervals along the lymphatic system. Several afferent lymphatic vessels 
bring in lymph, which percolates through the substance of the lymph node, and is 
drained out by an efferent lymphatic vessel103. 
  
Lymphangiogenesis occurs during both normal development and pathological 
conditions, including inflammation, lymphedema and metastasis of tumors106-108. The 
lymphatic vessels serve as a major route for metastatic spread of tumor cells from the 
primary site to regional lymph nodes, then possibly to distant organs86,88,109-118. 
However, little is known about possible structural and functional differences between 
healthy lymphatic vessels and tumoral lymphatic vessels. It is well known that tumor 
blood vessels usually consist of disorganized, leaky and tortuous vasculatures. Recent 
studies have demonstrated that peritumoral and intratumoral lymphatic vessels also 
consist of disorganized and leaky microvessels that might lack drainage function108. 
The structural irregularity and leaky features of tumoral lymphatic vessels might 
make them more susceptible for invasion by malignant cells119.  
 
 
1.2.3 Lymphangiogenic factors  
 
VEGF-C and VEGF-D were the first identified growth factors to activate LECs and 
stimulate lymphangiogenesis120,121. Recently, several new lymphangiogenic factors 
have been found. These lymphangiogenic factors appear to be functionally important 
for the development of the lymphatic system. 
 
 
1.2.3.1 Vascular endothelial growth factor family 
 
Among all known lymphangiogenic factors, VEGF-C and VEGF-D are the most potent 
lymphangiogenic factors, which play essential roles in regulation of physiological and 
pathological lymphangiogenesis. VEGF-C is a member of the VEGF family that are 
critical mediators of angiogenesis and lymphangiogenesis122.  
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VEGF-C directly stimulates the migration and proliferation of LECs in vitro, and 
stimulates lymphatic vessel growth in vivo. VEGF-C contributes to formation and 
maintenance of lymphatic vascular systems. During early embryogenesis, VEGF-C 
plays an important role in the development of the lymphatic system. It is expressed 
along with its receptor VEGFR-3 in regions where the initial lymphatic vessels sprout 
and develop. 
 
VEGF-C appears to play a role in inflammatory responses. It has been shown to 
induce lymphatic vessel growth in response to pro-inflammatory cytokines123. Both 
VEGF-C and VEGFR-3 are prominently expressed by activated macrophages122. 
 
VEGF-D binds to the same receptors as VEGF-C, VEGFR-2 and VEGFR-3. During 
early embryogenesis, VEGF-D is mostly expressed in the developing lung and skin, 
where it is thought to play a modifying role in lymphangiogenesis during embryonic 
development. In adults, VEGF-D is expressed in numerous tissues, including lung, 
heart and skeletal. VEGF-D appears to promote solid tumor growth and lymph node 
metastasis. It is a poor prognostic marker for many cancers in patients, such as 
colorectal, ovarian, prostate and lung cancers124-127. In experimental tumor models, 
VEGF-D induces growth of intratumoral lymphatics and promotes lymphatic 
metastasis128. Both VEGF-C and VEGF-D have direct effects on LECs in vitro, and 
have been shown to induce tumoral lymphangiogenesis and promote lymphatic 
metastasis when these factors are expressed at high levels in various human 
cancers124-127,129-133. 
 
VEGFR-3 is the LECs specific tyrosine kinase receptor which activates 
lymphangiogenic signals. In adults, VEGFR-3 expresses mainly on lymphatic 
endothelium28. VEGFR-3 was originally thought to be expressed specifically on the 
lymphatic endothelium134, but further studies demonstrated that VEGFR-3 is up-
regulated in the neovasculatures of tumors120. Both VEGF-C and VEGF-D directly 
bind to VEGFR-3 acting on LECs to induce cell proliferation and migration. It is 
reported that VEGFR-3 can form heterodimers with VEGFR-2 upon binding of 
VEGF-C and VEGF-D, which may lead to unique combinatorial signals by the 
intracellular domains of the two receptors135.  
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The VEGF-C/-D/VEGFR-3 signaling system is involved in the formation of the first 
lymphatic vessels in the embryonic development. The VEGF-C/-D/VEGFR-3 
signaling pathway plays a central role in regulation of physiological and pathological 
lymphangiogenesis136. Several indirect lymphangiogenic factors might induce 
lymphangiogenesis via activation of the VEGF-C/-D/VEGFR-3 signaling 
pathway45,108. 
 
VEGF-A is a key angiogenic factor over-expressed in most of human cancers. VEGF-
A can bind to VEGFR-2 to promote angiogenesis. VEGF-A has recently been found 
to stimulate lymphangiogenesis in various animal models137. VEGF-A inducing 
lymphangiogenesis suggests that this factor may not only have a major impact on 
tumor progression and angiogenesis, but also on tumor lymphatic metastasis. VEGF-
A-overexpressing tumors generally have a very fast growth rate due to the robust 
angiogenic response induced138.  
 
VEGF-A appears to promote new lymphatic sprouts from the pre-existing limbal 
lymphatic vessel in the lymphangiogenesis model. In the mouse corneal model, 
VEGF-A expressing viral vectors promoted the growth of functional lymphatic 
networks24.  
 
VEGF-A might promote lymphangiogenesis via both direct and indirect effects on 
LECs. VEGF-A downstream signaling cascade is mediated principally via VEGFR-2. 
VEGFR-2 was previously considered to be expressed exclusively on vascular 
endothelium. However, it has recently been shown that lymphatic endothelium also 
expresses VEGFR-2139. VEGF-A promotes survival, proliferation and migration of 
LECs via VEGFR-224. 
 
 
1.2.3.2 Fibroblast growth factor family 
 
FGF family involves in angiogenesis and lymphangiogenesis. FGF-2 has been shown 
to promote LECs proliferation, migration and assembly into capillary-like tube 
structures in vitro. In vivo, FGF-2 has been reported to stimulate lymphatic vessel 
growth indirectly via up-regulation of VEGF-C expression in vascular endothelial 
and perivascular cells in the cornea assay24,46,140. Blockage of VEGFR-3 signalling 
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suppresses FGF-2-induced lymphangiogenesis demonstrating that FGF-2 might 
stimulate lymphangiogenesis in dependent on VEGFR-3 signalling pathway in vivo 
24,46,140.  
 
FGFs/FGFR-1 plays an important role in the development and maintenance of a 
mature vascular network in the embryo. FGFR-1-mutant mouse embryos are 
developmentally retarded or even die during gastrulation stage. In recent years, some 
intimate cross-talk exists between FGF-2 and members of the VEGF-family during 
vasculogenesis, angiogenesis and lymphangiogenesis have been reported24,46,140. In 
paper II, we found that co-implantation of micropellets containing VEGF-C plus 
FGF-2 resulted in angiogenic synergism in the corneal tissue, suggesting that VEGF-
C and FGF-2 collaboratively promote corneal angiogenesis and lymphangiogenesis. 
FGF-2 directly promoted LEC proliferation and migration via activation of the 
FGFR-1–mediated signaling pathway in vitro, which demonstrated that FGF-2 is a 
direct lymphangiogenic factor. Interestingly, this FGF-2–induced lymphangiogenesis 
was completely inhibited by VEGFR-3 blockade in vivo. We found that the tip cell 
formation at the leading front of growing lymphatic vessels induced with FGF-2 
could be completely inhibited by VEGFR-3 blockade (paper II).  
 
 
1.2.3.3 Other lymphangiogensis factors 
 
IGF family has been demonstrated to induce lymphangiogenesis in several systems. 
For example, IGF-1 and IGF-2 induce lymphangiogenesis in a mouse cornea assay141. 
Interestingly, IGF-1R signalling was recently shown to positively regulate the 
expression of VEGF-A, VEGF-C and FGF-2142. This suggested that the IGF family 
might induce lymphangiogenesis, at least through an indirect mechanism. The IGF-
1R is expressed in most tissues, including vascular ECs. Both IGF-1 and IGF-2 act 
via IGF-1R to stimulate EC proliferation, migration and tube formation143. IGF-1R-
activation might indirectly induce intratumoral lymphatic vessel growth and thereby 
promote lymphatic metastasis. 
 
In PDGF family, PDGF-AA, -AB and -BB are able to promote lymphangiogenesis, 
while PDGF-BB is the most potent lymphangiogenic factor within this family69. 
PDGF-BB induces cell migration of LECs, suggesting its direct role in 
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lymphangiogenesis. Overexpression of PDGF-BB tumor tissues stimulates the growth 
of both intra- and peritumoral lymphatic vessels, resulting in increased lymphatic 
metastasis. The PDGFR-β has been detected in cancer patients with 
lymphangiomatosis, suggesting the clinical relevance of the PDGF/PDGFR signalling 
pathway in lymphatic malignancy and metastasis144.  
 
Ang-1 and Ang-2 were recently suggested to play the roles in the development of 
functional lymphatic vessels. Both Ang-1 and Ang-2 bind to tie-2 receptor expressed 
on LECs, indicating direct effects of Ang-1 and Ang-2 on lymphangiogenesis. Ang-2 
knockout mice display defects in the patterning and function of the lymphatic 
vasculature64. 
 
Hepatocyte growth factor (HGF) is reported to promote lymphangiogenesis145. C-Met 
is the receptor of HGF expressed in the newly formed lymphatic vessels of 
inflammatory tissues although quiescent lymphatics do not express this receptor. 
HGF involved in inducing the dilation of peritumoral lymphatics and lymphatic 
metastasis146-149.  
 
 
1.2.4 Lymphangiogenic inhibitors 
 
Current development of lymphangiogenic inhibitors is mainly focused on the VEGF-
C/VEGF-D/VEGFR-3 signalling pathway, including neutralization of VEGF-C and 
VEGF-D with soluble VEGFR-3150, and anti-receptor antibodies to block VEGFR-
3151. In this thesis, we showed that both FGF-2– and VEGF-C– induced 
lymphangiogenesis were completely inhibited by VEGFR-3 blockade, an anti-receptor 
antibody, in mouse models. In addition, it was reported that several drugs, such as 
celecoxib (Celebrex; Pfizer) and rofecoxib (Vioxx; Merck), are powerful inhibitors of 
lymphangiogenesis119. However, the therapy of lymphangiogenesis needs to be 
further studied. 
 
 
1.2.5 Inflammation and lymphangiogenesis 
 
Inflammation is associated with many physiological and pathological conditions, 
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including wound healing and tumor development. There is increasing evidence that 
inflammation contributes to angiogenesis, lymphangiogenesis and tumor 
metastasis152-158. Whereas the role of inflammation in angiogenesis is well studied, 
less is known about how acute and chronic inflammation contributes to 
lymphangiogenesis. 
 
It has been reported that several inflammatory cytokines might induce VEGF-C and 
VEGF-D expressions in several cell types via the downstream of NF-κB pathway. 
Inflammatory cells, such as macrophages attracted by inflammatory cytokines in 
several mouse models, have been shown to produce high level of lymphangiogenic 
factors, including VEGF-C and VEGF-D, to induce lymphangiogenesis. Several 
causative factors, such as interleukin-1 beta, transforming growth factor-beta, tumor 
necrosis factor-alpha and macrophage colony-stimulating factor, may be actively 
involved in macrophage-induced lymphangiogenesis157,159-161. There is growing 
evidence that macrophages play an important paracrine role in the growth of 
lymphatic vessels. The paracrine role of macrophages involves their secretion of 
VEGF-C and VEGF-D in stimulating lymphangiogenesis from pre-existing 
lymphatics. Lymphangiogenesis is also associated with chronic inflammation, such as 
Crohn's disease or rheumatoid arthritis162.  
 
Inflammatory responses in tumor tissues have been associated with malignant 
progression and lymphatic metastasis. Infiltration of inflammatory cells into tumor 
tissues might induce the growth of intratumoral lymphatic vessels, which in turn 
might promote lymphatic metastasis157,159-161. 
 
Alteration of macrophage phenotype and function has profound the effect on the 
development and progression of inflammation and malignancy. Macrophage 
depletion for controlling lymphangiogenesis may provide a novel approach for 
prevention and treatment of lymphatic-associated diseases. Moreover, the inhibitors 
of inflammatory pathways might suppress lymphangiogenesis and lymphatic 
metastasis in tumor. Anti-inflammatory drugs, such as COX-2 inhibitors and non-
steroid anti-inflammatory drugs have been reported to have potent anti-
lymphangiogenesis activity in tumor models163. 
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1.3 CANCER 
 
More than 35 years ago, Dr. Judah Folkman proposed that tumor growth and spread 
are dependent on angiogenesis. Today, angiogenesis is well known to promote 
growth, development and metastasis of tumors. It is widely accepted that in the 
absence of blood vessels tumors can not grow beyond the size of a few mm3 or 
metastasise to distant organs5,7,18. In addition to hemangiogenesis, various types of 
tumors often contain lymphatic vessels, which may facilitate lymphatic metastasis. 
However, the role of tumor lymphatic vessels in promoting metastasis remains poorly 
understood. Cancer metastasis employs complex processes that are collectively 
termed as the metastatic cascade, which involves multiple-step defined mechanisms. 
A clinical detectable metastatic mass represents the ultimate consequence of the 
complex metastatic cascade that includes dissemination of tumor cells from the 
primary site; intravasion of tumor cells into the circulation or lymphatic system; 
transport of tumor cells along blood circulation or lymphatic system to distal tissues 
or organs; extravasation of tumor cells from the circulation of lymphatic system; 
formation of the primary metastatic niche in distal tissues; manipulation of metastatic 
microenvironment; and regrowth of metastatic nodules to a visible metastatic mass.  
 
 
1.3.1 Tumor angiogenesis 
 
Angiogenesis is well known to promote growth, development and metastasis of 
tumors. Metabolism and growth of cells require adequate oxygen and nutrition supply, 
as well as removal of metabolites. Tumor-derived angiogenic factors act in a 
paracrine manner to recruit blood vessels from the surrounding stroma into the tumor 
to supply oxygen and nutrition, allowing survival and further growth of the tumor13. 
VEGF is one of the key angiogenic factors that contributes to the onset and progression 
of tumors. In tumor environment, ischemia and hypoxia in tumor tissue result in 
marked production of VEGF-A followed by a new robust angiogenic response.  
 
The vasculature in tumor tissue is structurally and functionally abnormal, highly 
disorganized, tortuous, dilated and leaky164. In addition, ECs within tumor vessels are 
irregularly shaped and disorganized. Tumor vessels have widened interendothelial 
junctions, numerous openings in their walls, and a discontinuous or even totally 
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absent basement membrane, resulting in the intravasion of tumor cells into the 
circulatory system, and thus allow metastatic dissemination of invasion-competent 
cells165.  
 
In clinics, many tumors are constantly hypoxic due to poorly perfused and low 
quality blood vessels because tumors express high levels of VEGF. Then VEGF 
might induce high degrees of leakiness and tortuosity of the tumor vasculature166. In 
paper I, we showed a hypoxic zebrafish model to monitor tumor cell dissemination, 
invasion and metastasis in living fish at the single cell level. We found that tumor 
hypoxia played an important role in tumor cell dissemination and distant metastasis.  
 
 
1.3.2 Tumor lymphangiogenesis 
 
In addition to angiogenesis, various types of tumors often contain lymphangiogenesis, 
which may facilitate lymphatic metastasis. A clinically detectable cancer metastasis 
in lymph nodes employs complex processes, including the dissemination of tumor 
cells from the primary site to the lymphatic vessels, the transport of tumor cells along 
lymphatic system, the extravasation of tumor cells from the lymphatic system to the 
lymph nodes, the settlement of tumor cells in lymph nodes, and the growth of the 
metastatic lesion to a detectable mass. 
 
Regional lymph node metastasis represents the first step of tumor dissemination for 
cancers, which is reported in breast cancer, colon cancer and prostate cancer. 
Regional lymph nodes metastasis of malignant tumors is one of the early signs of 
cancer spread in patients. In clinics, the extent of lymph node metastasis is a major 
determinant for the staging and the prognosis of cancer patients, which often guides 
therapeutic decisions. It is reported that the density of tumoral lymphatic vessels 
correlates with the incidence of lymph node metastasis and poor prognosis in some 
human cancers167-176. It is known that tumor cells can gain access to the lymphatic 
system either by inducing the growth of intratumoral lymphangiogenesis or by 
inducing the growth and dilation of peritumoral lymphangiogenesis during tumor 
expansion via growth factor production, such as VEGF88,125,142,177,178. 
 
However, the role of tumor lymphangiogenesis in facilitating metastasis remains 
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poorly understood. Recently, the improved lymphatic-specific markers such as 
VEGFR-3, lymphatic LYVE-1, Prox-1 and podoplanin have made it possible to study 
the formation of tumor-associated lymphatic vessels, and to investigate the 
contributions and relationship of different factors in inducing lymphangiogenesis and 
lymphatic metastasis. 
 
It is well known that VEGF-C and VEGF-D bind to VEGFR-3 to induce tumor 
lymphangiogenesis and promote the formation of lymph node metastasis179,180. This 
VEGF-C/-D/VEGFR-3 signaling pathway plays the central role in regulation of 
lymphangiogenesis and lymphatic metastasis136. The other indirect lymphangiogenic 
factors maybe induce lymphangiogenesis via activating the VEGF-C/-D/VEGFR-3 
signaling pathway. Conversely, inhibitors of the VEGF-C/-D/VEGFR-3 signalling 
pathway, such as VEGFR-3 blocking antibodies, may have the potential to block 
lymphatic tumor spread119. 
 
In the tumor microenvironment, tumor cells, stromal cells and inflammatory cells 
produce multiple lymphangiogenic factors that might stimulate tumoral 
lymphangiogenesis. In addition to VEGF-C and VEGF-D, other growth factors have 
also been shown to participate in the molecular mechanism of lymphangiogenesis, 
including FGF-2, PDGF family and IGF family. Various angiogenic factors often co-
exist in the tumor microenvironment and they often cross-communicate with different 
signaling pathways. Although the individual roles of various angiogenic factors in 
promoting angiogenesis and lymphangiogenesis are relatively well studied, the 
interplay between them in the tumor environment remains poorly understood. In the 
paper II of this thesis, we chose FGF-2 and VEGF-C, two commonly expressed 
potent angiogenic factors, to investigate the interplay between them in promoting 
lymphangiogenesis and lymphatic metastasis (Figure 2).  
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Figure 2. FGF-2 and VEGF-C collaboratively promote tumor lymphangiogenesis and 
lymphatic metastasis. FGF-2 activates FGFR-1 on LECs to stimulate LEC proliferation and 
migration. VEGF-C activates VEGFR-3 receptor on LECs, leading to LEC tip formation, 
proliferation and migration. VEGFR-3–triggered tip cell formation is a prerequisite for FGF-
2–induced lymphangiogenesis. (adapted from paper II). 
 
 
Although it is well known that induction of tumor angiogenesis in solid tumors is to 
supply oxygen and nutrients for tumor cells and removes metabolic waste products, it 
is poorly understood how and why tumors induce lymphangiogenesis. Compared to 
the blood vascular system, the lymphatic system appears to be more accessible for 
tumor cell dissemination. Unlike blood capillaries, lymphatic capillaries consist of a 
single, thin LECs layer. LECs have poorly developed junctions with frequent large 
inter-endothelial gaps. LECs lack a continuous basement membrane, and adjacent 
cells lack junctions and instead overlap at their edges. In addition, lymphatic 
capillaries are not coated with pericytes or vSMCs. These structural features of 
 20 
lymphatics make them more accessible for intravasion of tumor cells into the 
lymphatic system and extravasation of tumor cells from the lymphatic system to 
regional lymph nodes to establish metastatic niche in distal tissues. In addition, many 
solid tumors have increased interstitial fluid pressure (IFP). The lymphatic system 
may lower IFP in solid tumors to increase blood perfusion to facilitate tumor growth. 
Furthermore, the interaction between LECs and tumor cells has been shown to 
facilitate tumor-cell invasion into the lymphatics. LECs produce cytokines that can 
guide the tumor cells toward the lymphatic vessels. For example, CCL21 produced by 
the LECs appears to attract some tumor cells that express its receptor CCR7 into 
lymphatic vessels181-184. Lymphangiogenesis might contribute to tumor growth, 
invasion and metastasis by several mechanisms. The biology and mechanism of 
tumor lymphangiogenesis and lymphatic metastasis need to be studied further.  
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2 AIMS 
I. To develop a novel zebrafish model to study the early steps of the metastatic 
cascade (Paper I).   
II. To study the interplay between FGF-2 and VEGF-C in promoting lymphatic 
metastasis (Paper II).  
III. To develop a unique in vivo model to study lymphangiogenesis induced by 
various factors (Paper II -III).  
IV. To study the impact of clinical available antiangiogenic drugs on healthy 
vasculatures and revealed potential sites for antiangiogenic drug-related side effects 
(Paper IV). 
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3 METHODS  
 
3.1 Zebrafish tumor model  
 
In paper I, we develop a zebrafish metastatic model to take the advantage of the 
transparent nature of zebrafish embryos to study molecular mechanisms of tumor cell 
invasion, dissemination and metastasis in association with angiogenesis and hypoxia 
in single cell level in vivo. The EGFP positive vasculature of transgenic 
Tg(fli1:EGFP) zebrafish embryos is very clear under microscope. Morpholino was 
used for reverse genetics to silence host gene functions. We developed a semi-closed 
system where the water was pre-calibrated to a particular oxygen level to established 
hypoxic conditions to the zebrafish. We implanted murine T241 fibrosarcoma cells, 
Lewis lung carcinoma (LLC), or human tumors cells into the perivitelline cavity of 
two days old fish embryos of transgenic Tg(fli1:EGFP) zebrafish under normoxic or 
hypoxic conditions. The embryos were incubated with water containing 0.2 mM 1-
phenyl-2-thio-urea (Sigma) to prevent pigmentation. The two days old zebrafish 
embryos were anesthetized and injected with glass capillaries needles in 
microinjector. The tumor cells were labeled with the red fluorescent dye DiI before 
injection. Injected embryos were examined every other day for monitoring tumor 
growth and invasion using a fluorescent microscope (Nikon Eclipse C1, Japan).  
 
 
3.2 Mouse tumor model 
 
Different kinds of mice models have been used to investigate tumor growth and 
metastasis. In paper II, tumors were grown syngeneically to study the interplay of 
FGF-2 and VEGF-C on tumor growth, tumor-associated angiogenesis, 
lymphangiogenesis and metastasis. Approximately 1 × 106 tumor cells were 
subcutaneously implanted in the central position along the dorsal midline of each 
mouse. Half the numbers of FGF-2– and VEGF-C–tumor cells were mixed for co-
implantation experiments (six mice per group). Tumor growth was measured every 
other day and tumor volumes were calculated. Then the subcutaneously grown 
primary tumors located at the middle dorsum were surgically removed at the size of 
1.5 cm3 under anesthetic conditions (within the ethical limit). Open wounds were 
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sutured and mice were given painkiller in two consecutive days (Temgesic, 0.1 mg/kg, 
twice a day). Typically, two weeks after tumor removal, visible sentinel lymph node 
metastases were detectable in bilateral subaxillary lymph nodes of VEGF-C– or FGF-
2 plus VEGF-C tumor-bearing mice. At this time point, tumor-bearing mice were 
sacrificed and various organs, including lymph nodes, lung, liver, spleen, kidney and 
brain were collected for histological analysis. 
 
A number of histological techniques are used to investigate angiogenesis and 
lymphangiogenesis in tumor tissue, such as H&E staining for general morphology, 
CD31 staining for blood vessel density, and LYVE-1 staining for lymphatic vessel 
density. 
 
 
3.4 Mouse corneal model 
We developed a mouse corneal model to study lymphangiogenesis induced by 
various factors. The steps of this study include: preparation of micropellets, corneal 
implantation, immunohistochemistry and data analysis. Firstly, we created a 
micropocket in the cornea of each mouse. Then we inserted a micropellet into the 
corneal micropocket. Corneal angiogenic responses were detected on day 5 or 6 after 
implantation. Unlike blood vessels, lymphatic vessels are not perfused with red blood 
cells and thus remain invisible under light microscopy. So we used 
immunohistochemical staining of corneal tissues with lymphatic-specific markers, 
such as LYVE-1, to study the fine structure of lymphatic microvessels. After careful 
dissection, the entire corneal tissue should be used for whole-mount staining with 
double or triple immunostaining using combinations of several antibodies specific for 
blood and lymphatic vessels, to study the relationships between blood vessels and 
lymphatic vessels. At last, the stained corneal tissues should be analyzed using a 
multichannel confocal microscope that detects positive signals in different colors. 
 
 
3.5 Confocal microscopy of whole-mount specimens 
 
In this thesis, we mainly used a combination of CD31 and LYVE-1 antibodies in 
whole mount staining to detect blood- and lymphatic vessels in mouse corneas (paper 
II, III) and tumor tissues (paper II). To further confirm lymphatic vessel identity, we 
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have co-stained the corneal tissue with other specific markers such as VEGFR-3 
(paper III). 
 
Laser Scanning Confocal Microscopy is an advanced microscopic technique routinely 
used for generating high resolution images and three-dimensional reconstructions of 
vasculars. Immunostained positive signals and EGFP positive tumor cells were 
detected using a Nikon C1 Confocal microscope (Nikon) or a Zeiss Confocal 
LSM510 microscope (Carl Zeiss). For 3D images of each dataset, scanning five to six 
layers were assembled using a confocal microscope software program (EZ-C1). 
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4 RESULTS  
 
4.1 HYPOXIA-INDUCED ANGIOGENESIS STIMULATES METASTASIS IN 
A ZEBRAFISH TUMOR MODEL (PAPER I)  
 
Tissue hypoxia is known to significantly contribute to tumor invasion and 
metastasis185-188. Hypoxia is also an effective driving force for angiogenesis which is 
not only essential for primary tumor growth but also facilitates tumor invasion and 
metastasis. However, the mechanisms and detailed processes underlying hypoxia-
associated metastasis remain poorly understood.  
 
Our aim was to take the advantage of the transparent nature of zebrafish embryos to 
visualize under normoxic and hypoxic conditions marked human or mouse tumor cell 
migration and invasion in association with tumor angiogenesis. This zebrafish 
metastatic model allows us to monitor dissemination of single tumor cells from 
primary sites in the living body to study the role of hypoxia in tumor invasion and 
metastasis. 
 
In this study, we implanted murine T241 fibrosarcoma cells into the perivitelline 
cavity of two days old fish embryos of transgenic fli1:EGFP zebrafish under 
normoxia or hypoxic conditions. The cells were labeled with the red fluorescent dye 
DiI before injection. After exposing the embryos to 7.5 % air saturation for three days, 
we observed significant numbers of tumor cells disseminated from primary sites, 
invaded into neighboring tissues, and metastasized to distal parts of the fish body 
under hypoxic conditions in contrast to normoxic conditions. In addition, we found 
that hypoxia significantly stimulated neovascularization and tortuosity of the tumor 
vasculature. 
 
Similarly, overexpression of VEGF-A by the transfected tumor cells, which is well-
correlated with increased neovascularization and tortuosity of the tumor vasculature, 
also led to tumor cells dissemination and metastasis. Furthermore, we found that 
inhibition of VEGF receptor signaling pathways by sunitinib or VEGFR-2 
morpholinos abrogated the VEGF-induced tumor cell dissemination and metastasis. 
All these results were similarly repeated with another murine tumor cell line, LLC.  
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Finally, we used this zebrafish model to study the role of hypoxia-induced 
angiogenesis in mediation of tumor cell dissemination and metastasis. We used 
sunitnib to inhibit VEGF receptors under hypoxia, and found that VEGFR blockade 
effectively blocked hypoxia-induced tumor angiogenesis and metastasis. 
 
We also used this tumor model to study the early events of dissemination and 
metastasis of human tumor cells. We chose the low metastatic human ovarian 
carcinoma cell line OVCAR 8 and highly metastatic human MDA MB 231 breast 
cancer cell line. Our results showed that most of the injected MDA MB 231 cells 
disseminated whereas OVCAR 8 mostly grew in situ. The different capacities of 
dissemination resulted in difference of metastatic potentials between these two cell 
lines.  
 
These findings demonstrate that hypoxia- and VEGF-induced pathological 
angiogenesis can promote tumor dissemination, invasion and metastasis in the 
zebrafish model. Furthermore, this zebrafish model might be used to discriminate 
high and low metastatic potentials of human cancers and to predict prognosis, and 
provide compelling evidence on the beneficial effects of clinically available anti-
VEGF drugs for cancer therapy. 
 
 
4.2 THE INTERPLAY BETWEEEN FGF-2 AND VEGF-C IN PROMOTING 
LYMPHANGIOGENESIS AND LYMPHATIC METASTASIS (PAPER II) 
 
In addition to hemangiogenesis, various types of tumors often contain lymphatic 
vessels, which may facilitate lymphatic metastasis. The entire metastatic process is 
tightly linked to the intimate interactions between tumor cells and hemvascular and 
lymphvascular systems. 
 
Tumors can produce various angiogenic factors to stimulate angiogenesis and 
lymphangiogenesis. Various angiogenic factors often co-exist in the tumor 
microenvironment and they often cross-communicate with different signaling 
pathways. Although the individual roles of various angiogenic factors in promoting 
angiogenesis, lymphangiogenesis and tumor metastasis are relatively well studied, the 
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interplay between them in the tumor environment remains poorly understood. To 
study interplay between various angiogenic factors in promoting lymphangiogenesis, 
we chose FGF-2 and VEGF-C, two commonly expressed angiogenic factors for our 
study. 
 
Both VEGF-C and FGF-2 are potent angiogenic factors commonly expressed in 
various tumor tissues. The expression levels of VEGF-C and FGF-2 have been 
correlated with tumor growth, progression and metastasis189. In this study, we 
investigated the interplay between FGF-2 and VEGF-C in promoting 
lymphangiogenesis and metastasis in various in vivo models.  
 
We established a corneal lymphangiogenesis assay to study the factor-induced 
lymphangiogenesis and vascular structures in the avascular corneal tissue. In brief, 
FGF-2, VEGF-C, or FGF-2 plus VEGF-C with a slow-release polymer composed of 
sucralfate and hydron, were implanted into the mouse cornea. Then the corneas were 
dissected at day 6 and double immunostained with CD31 and LYVE-1 antibodies.  
 
As expected, both VEGF-C and FGF-2 were also able to stimulate corneal 
angiogenesis and lymphangiogenesis. Interestingly, co-implantation of micropellets 
containing VEGF-C plus FGF-2 resulted in angiogenic synergism in the corneal 
tissue, which suggested that VEGF-C and FGF-2 collaboratively promote corneal 
angiogenesis and lymphangiogenesis. In contrast, implantation of the slow-release 
polymer soaked in PBS, as the negative control, did not induce angiogenesis or 
lymphangiogenesis, and the only vessels detected in these negative control corneas 
were the pre-existing lymphatics of the limbus. 
 
We used LECs to do in vitro proliferation and migration assays to study the cellular 
basis of lymphangiogenic synergism between FGF-2 and VEGF-C. Both VEGF-C 
and FGF-2 potently stimulated human LECs proliferation alone, whereas FGF-2 plus 
VEGF-C significantly increased cell proliferation. RT-PCR analysis demonstrated 
that FGFR-1 expressed in LECs is a crucial receptor that mediates the FGF-2-induced 
lymphangiogenesis, as VEGFR-3 is the crucial receptor of VEGF-C-induced 
lymphangiogenesis. Our findings also suggested that there was additive 
lymphangiogenic activity when both FGF-2 and VEGF-C are co-exposed to LECs, 
which is caused by the significant up-regulation of fgfr-1 and vegfr-3 expression 
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stimulated by the two factors. The VEGFR-3 signaling system or the FGFR-1 
signaling system was blocked by siRNA or anti–VEGFR-3 and anti-FGFR-1 
neutralizing antibodies.  
 
These potent anti-lymphangiogenic activities were also observed in vivo. FGFR-1 
neutralizing antibody significantly inhibited FGFR-2 plus VEGF-C–induced 
angiogenesis and lymphangiogenesis in corneas. As expected, VEGFR-3 neutralizing 
antibody completely blocked VEGF-C–induced lymphangiogenesis. Interestingly, 
VEGFR-3 neutralizing antibody also completely blocked FGF-2–induced 
lymphangiogenesis in corneas. We were very surprised because the same VEGFR-3 
blockade did not significantly affect FGF-2–induced LECs proliferation and 
migration in vitro.  
 
Recently, some groups have reported that the formation of tip endothelial cells is an 
essential process in angiogeneisis and lymphangiogenesis151,190. In our study, we 
found that both FGF-2 and VEGF-C were able to induce tip formation at the leading 
front of the growing lymphatics, and coimplantation of these two factors resulted in 
an additive effect on the tip formation. Additionally, we found that VEGFR-3 
blockade completely inhibited all the lymphatic tip formation in the VEGF-C–, FGF-
2–, or FGF-2 plus VEGF-C–induced tip formation at the leading front of the 
lymphatics. These findings suggested that VEGFR-3–induced tip formation is a 
prerequisite for lymphangiogenesis. 
 
We also used a mouse tumor metastatic model, in which tumors located 
subcutaneously at the middle dorsum were surgically removed at the size of 1.5 cm3 ,  
to study the angiogenic and lymphangiogenic synergisms of FGF-2 and VEGF-C. 
The transfected murine fibrosarcoma cell lines which expressed FGF-2 or VEGF-C 
were subcutaneously implanted in immune deficient SCID mice. Both FGF-2 and 
VEGF-C significantly promoted tumor growth, hemangiogenesis and 
lymphangiogenesis. Interestingly, implantation of the same number of tumor cells 
consisting of 50% FGF-2 and 50% VEGF-C cells to the mice resulted in a markedly 
accelerated tumor growth, a higher density of disorganized vascular networks 
including intratumoral lymphatic vessels, and highly dilated peritumoral lymphatics. 
Additionally, we found more EGFP tumor cells in the dilated peritumoral lymphatics 
induced by FGF-2 plus VEGF-C.  
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Furthermore, we studied collaborative potentials of FGF-2 and VEGF-C in promoting 
hematogenous and lymphatic metastasis. We checked the lungs and sentinel lymph 
nodes of these tumor-bearing mice. More than 70% of FGF-2 plus VEGF-C tumor-
bearing mice had pulmonary metastases, wheares no pulmonary metastasis was 
detected in FGF-2 tumor-bearing mice, and only less than 40% of VEGF-C tumor-
bearing mice had pulmonary metastases. On the other hand, 100% of FGF-2 plus 
VEGF-C tumor-bearing mice carried metastatic sentinel lymph nodes, and both 
weights and volumes of these metastatic lymph nodes were significantly bigger than 
the other groups. Collectively, our results demonstrated that FGF-2 and VEGF-C 
collaboratively stimulate hematogenous and lymphatic metastasis. 
 
   
4.3 MOUSE CORNEAL MODEL IN STUDYING LYMPHANGIOGENESIS 
(PAPER III) 
 
As for lymphangiogenesis, the formation of new lymphatic networks is a multistep 
process that involves LECs proliferation, migration, lymphatic tube formation, 
maturation and remodeling, all of which are tightly regulated by lymphangiogenic 
factors and inhibitors24,69,191,192. Studying the inhibition of lymphangiogenesis might 
potentially offer a new opportunity for the treatment of cancer metastasis because the 
intratumoral and peritumoral lymphangiogenesis have been associated with cancer 
metastasis.  However, although there are several in vitro and in vivo assays to study 
LECs proliferation, migration and tube formation, there has been lacking appropriate 
and powerful in vivo assay systems that allow us to study lymphangiogenesis 
quantitatively. 
 
In this study, we developed a unique in vivo model to study lymphangiogenesis 
induced by various factors. In comparison with other in vivo lymphangiogenesis 
models, the corneal tissue is avascular for both blood vessels and lymphatic vessels. 
This model offers us a unique opportunity to study lymphatic vascular formation, 
structure, stability and remodeling. The avascular feature of the corneal tissue makes 
this model useful for a quantitative assessment of lymphangiogenesis. We took the 
advantage of the avascular nature of the mouse corneal tissue and implant various 
growth factors/cytokines alone or in combinations to quantitatively study 
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lymphangiogenesis and lymphatic structures. We have described this model in 
studying the interplay between FGF-2 and VEGF-C in promoting lymphangiogenesis 
and metastasis (paper II) 
 
As the details described in the methods part of my thesis, the steps of this study 
include: preparation of micropellets, corneal implantation, and immunohistochemistry 
and data analysis. This protocol describes a unique in vivo animal model which 
allows us to investigate the lymphangiogenesis in an ideal condition in which the 
amount of lymphangiogenic factor, the size of the micropellet, the implantation site 
and the time point of responses are all well defined. 
 
 
4.4 ANTI-VEGF DRUG-INDUCED VASCULAR ALTERATION IN HEALTHY 
TISSUES (PAPER IV) 
 
Humanized VEGF neutralizing monoclonal antibodies, such as bevacizumab, have 
been widely used for treatment of various human cancers, including lung cancer, 
glioblastoma and RCC. However, systemic impacts of anti-VEGF or anti-VEGFR 
drugs in host healthy vasculatures remain poorly understood. In paper IV, we chose 
VEGF and VEGFR specific blockades to study the impact of antiangiogenic drugs on 
healthy vasculatures and to reveal antiangiogenic drug related side effects. 
 
We used three specific anti-VEGF agents to block VEGF-induced biological 
activities and study the impact of VEGF specific blockades on vasculatures in various 
healthy tissues: a rabbit anti-mouse neutralizing monoclonal antibody (BD0801)193; a 
rat anti-mouse VEGFR-1 neutralizing monoclonal antibody (MF-1)194-196; and a rat 
anti-mouse VEGFR-2 neutralizing monoclonal antibody (DC101)194-196.  
 
We first analyzed vasculatures in endocrine organs, such as thyroid, adrenal cortex 
and pancreatic islets that are known to express relatively high levels of VEGF. We 
observed significant reduction of vascular density in thses endocrine organs in 
response to both anti-VEGF and anti-VEGFR-2 blockades. These data demonstrate 
that VEGF/VEGFR-2 signaling pathway plays a pivotal role in maintenance of 
vascular homeostasis in these endocrine organs.  
 
We also studied the impact of antiangiogenic drugs in other healthy tissues. We found 
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that VEGF and VEGFR-2 specific blockades significantly decreased vascular density 
in gastrointestinal tracts and the female reproductive system, whereas VEGFR-1 
increased vascular density in this tissue. In kidney, liver and pancreatic acini area, 
anti-VEGF and anti-VEGFR-2 blockade produced a similar vascular regressive 
phenotype, but anti-VEGFR-1 blockade did not affect the vessel density in these 
organs. 
 
Interestingly, we found that anti-VEGF-induced thyroid vascular regression was 
completely reversible after discontinuation of anti-VEGF treatment. The vascular 
density and architecture returned to nearly the same levels as the untreated animals 
after two weeks cessation of VEGF blockade.  
 
It is well known that vascular fenestrations are crucial for maintenance of endocrine 
organ functions1,197-199. Therefor, we next investigated the impact of anti-VEGF drugs 
on alteration of vascular fenestrations and endocrine functions in thyroid gland. As 
expected, VEGF blockade completely suppressed the formation of endothelial 
fenestrations in thyroid vessels. This result suggested that VEGF acts as a 
homeostatic factor for maintenance of vascular fenestrations in thyroid. We next 
treated the mice with VEGF blockade for a prolonged period of four weeks to further 
study the functional impact of anti-VEGF treatment in modulation of thyroid gland 
functions. We found that the circulating level of the predominant thyroid hormone 
free thyroxine (T4) was significantly decreased in the VEGF blockade-treated mice. 
The endocrine function of thyroid gland was impaired after prolonged treatment with 
VEGF blockade. 
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5 DISCUSSION 
 
5.1 METASTATIC CASCADE STUDIED IN ZEBRAFISH MODEL (PAPER I) 
 
Metastatic cascade consists of multiple-step defined mechanisms, including 
dissemination of tumor cell from the primary site; intravasion of tumor cells into the 
circulation; transport of malignant cells via blood circulation or lymphatic systems to 
distal tissues or organs; extravasation of tumor cells from the circulation of lymphatic 
system; formation of the primary metastatic niche in distal tissues; manipulation of 
metastatic microenvironment; and regrowth of metastatic nodules to a visible 
metastatic mass. Although advances of imagine techniques allows detection of 
relative small sizes of tumors in cancer patients and in experimental animal models, 
the early onset of metastatic processes remains unknown. It is known that hypoxia is 
an effective driving force for angiogenesis, but the mechanisms and detailed 
processes underlying hypoxia-associated metastasis remain poorly understood. It is 
important to establish an ideal animal model to investigate early steps of tumor cell 
dissemination and metastasis under hypoxic condition.  
 
We develop a zebrafish metastatic model that allows us to take the advantage of the 
transparent nature of zebrafish embryos to monitor dissemination of single tumor 
cells from primary sites in the living body under different conditions, such as 
normoxic and hypoxic conditions, to study tumor cell migration and invasion in 
association with tumor angiogenesis.  
 
We have found that tumor angiogenesis is essentially required for tumor cell invasion 
and dissemination. Hypoxia and VEGF significantly contribute to early events of the 
metastatic cascade. Hypoxia significantly increases tumor cell dissemination, 
invasion and metastasis by activation of VEGF, and its receptor-mediated signaling 
pathway. It is known that VEGF induces disorganized, leaky and tortuous 
vasculatures, which we also observed clearly in our zebrafish model. The 
disorganized vasculatures induced by VEGF are susceptible for malignant cell 
invasion. Additionally, outgrowth of blood vessels in tumors and perfusion of VEGF-
induced vessels could act as an attractants for tumor cell dissemination, invasion and 
metastasis. 
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Utilizing the the zebrafish model, our study provides evidence of hypoxia- and 
VEGF-induced pathological angiogenesis in promoting tumor cell dissemination, 
invasion and metastasis to distal sites at the single cell level. These findings further 
provide evidence on the beneficial effects of clinically available anti-VEGF drugs for 
the treatment of human cancers. 
 
 
5.2 FGF-2 AND VEGF-C COLLABORATIVELY PROMOTE 
LYMPHANGIOGENESIS AND LYMPHATIC METASTASIS (PAPER II) 
 
Tumors can produce various angiogenic factors to stimulate angiogenesis and 
lymphangiogenesis. In contrast to the extensive studies on tumor-associated 
angiogenesis, little is known about the mechanisms by which tumor stimulates 
lymphangiogenesis, and how tumor cells gain entry to the lymphatic system. Various 
angiogenic factors often co-exist in the tumor microenvironment and they often cross-
communicate with different signaling pathways. Although the individual roles of 
various angiogenic factors in promoting angiogenesis are relatively well studied, the 
interplay between them in the tumor environment remains poorly understood. 
 
In this study, we chose FGF-2 and VEGF-C, two commonly expressed potent 
angiogenic factors, to investigate the interplay between them in promoting 
lymphangiogenesis and lymphatic metastasis.  
 
There is no doubt that VEGF-C is a critical lymphangiogenic factor contributing to 
lymphangiogenesis. Both VEGF-C and FGF-2 induce proliferation and migration of 
LECs in vitro and lymphangiogenesis in vivo. FGF-2 directly promotes LECs 
proliferation and migration via activating the FGFR-1–mediated signaling pathway in 
vitro, which demonstrats that FGF-2 is a direct lymphangiogenic factor. But this 
FGF-2–induced lymphangiogenesis is completely inhibited by VEGFR-3 blockade in 
vivo. The tip cell formation at the leading front of growing lymphatic vessels induced 
with FGF-2 could be completely inhibited by VEGFR-3 blockade. Our results have 
suggested that LEC tips formation is an essential process for lymphatic vessel growth, 
and this process maybe tightly controlled by the VEGFR-3 signaling system. 
VEGFR-3 signaling system may play a pivotal role in lymphangiogeneisis triggered 
by other lymphangiogenic factors. However, there are still some questions included in 
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this case. For example, how does VEGFR-3 become activated? Does FGF-2 induce 
VEGF-C/-D expression or transactivate the VEGFR-3 signaling in the absence of 
these ligands? Do other factors induce lymphangiogenesis in vivo depending on the 
VEGFR-3 signaling system?  
 
FGF-2 and VEGF-C also display marked additive activity in stimulation of 
hemangiogenesis. These activitions are completely insensitive to VEGFR-3 blockade. 
Although the tip cell formation at the leading edge of angiogenic vessels is probably 
also essential for hemangiogenesis, this process does not seem to require activation of 
VEGFR-3, which is not prominently expressed in blood vessels. 
 
Lymphatic vessels provide one of the main routes for tumor cell dissemination, 
especially to regional lymph nodes. We have found that FGF-2 plus VEGF-C in the 
tumor microenvironment leaded to increased bloodstream and lymphatic metastasis. 
The intratumoral lymphatic vessels are highly disorganized and premature, which are 
susceptible features for facilitating tumor-cell dissemination and intravasation into 
lymphatics. Furthermore, peritumoral lymphatic vessels are highly dilated. These 
disorganized intratumoral lymphatic vessels and the dilated peritumoral lymphatic 
vessels may substantially contribute to lymphatic metastasis. Once metastasized to 
sentinel lymph nodes, the growth of metastases is further dependent on 
hemangiogenesis. Then the tumor cells can be further spread to other tissues and 
organs, and become metastatic masses in distal organs. 
 
In this study, we have showed that FGF-2 and VEGF-C collaboratively stimulate 
lymphangiogenesis in vivo, probably by enhancing the VEGF-C/VEGFR-3–induced 
LEC tip cell formation and FGF-2–triggered proliferative signals. It is important to 
develop therapeutic agents that interfere with the interplay between various tumor 
angiogenic factors. 
 
 
 
5.3 CONTRIBUTION OF MOUSE CORNEAL MODEL IN 
LYMPHANGIOGENESIS (PAPER III) 
 
In contrast to the extensive studies on angiogenesis, less is known about the 
mechanisms of lymphatic system. The formation of new lymphatic networks involves 
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LECs proliferation, migration, lymphatic tube formation, maturation and remodeling. 
This process is tightly regulated by lymphangiogenic factors and inhibitors.  
 
In this protocol, we have described an in vivo mouse corneal model which is used to 
study lymphangiogenesis induced by various factors. The main advantage of this 
corneal lymphangiogenesis model is that it allows us to study the lymphatic vessel 
formation in an avascular tissue for both blood and lymphatic vessels, thus avoiding 
any pre-existing vascular background. The avascular feature of the corneal tissue 
makes this model useful for a quantitative assessment of lymphangiogenesis. We take 
the advantage of this avascular nature of the mouse corneal tissue and implant various 
growth factors to quantitatively study lymphangiogenic stimulus–induced newly 
formed lymphatic vessels107,200. The amount of lymphangiogenic factor, the size of 
the micropellet, the implantation site and the time point of responses can be well 
defined in the absence of pre-existing vascular background in this mouse corneal 
model. So the structure, formation and architecture of lymphatic vessels induced by 
various factors can be studied and compared accurately.  
 
Furthermore, this corneal lymphangiogenesis model allows the investigation of the 
joint effects of various promotors or anti-lymphangiogenic inhibitors on 
lymphangiogenesis. For example, this model allows us to study the interplay between 
FGF-2 and VEGF-C in lymphangiogenesis and metastasis (paper II). Thus, we could 
use this corneal lymphangiogenesis model not only for the investigation of structural 
and functional aspects of lymphatic vessels, but also for therapeutic assessment of 
anti-lymphangiogenic compounds. 
 
 
 
5.4 THE IMPACTS OF ANTI-VEGF DRUGS IN HEALTHY TISSUES 
(PAPER IV) 
 
Bevacizumab, the humanized VEGF neutralizing monoclonal antibody, has been 
widely used for treatment of various human cancers, such as lung cancer, 
glioblastoma and RCC since it was approved by US FDA in 200470-76. FDA also 
approved other antiangiogenic drugs in the treatment of human cancers such as RCC. 
Tyrosine kinase inhibitors that block VEGFRs such as sunitinib, sorafenib and 
pazopanib are commonly used in clinics. Additionally, bevacizumab in combination 
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with chemotherapy has become the first-line standard care for treatment of several 
cancers, including RCC, non-small cell lung carcinoma and gastrointestinal stromal 
tumors73,74,201-203.  
 
On the other hand, it has been known that these anti-VEGF drugs in treatment of 
cancer patients have a broad impact on vasculatures in healthy tissues and organs 
which induces a range of adverse effects such as hypertension, renal vascular injury, 
or congestive heart failure. However, systemic impacts of these anti-VEGF or anti-
VEGFR drugs in healthy vasculatures and healthy tissues and organs remain poorly 
understood. In paper IV, we chose VEGF and VEGFR specific blockades to study the 
systemic impact of anti-VEGF drugs in mice healthy vasculatures and healthy tissues. 
 
We have observed significant reduction of vascular density in endocrine organs, 
gastrointestinal tracts and the female reproductive system. VEGF/VEGFR-2 signaling 
pathway plays a pivotal role in maintenance of vascular homeostasis in these healthy 
tissues and organs. VEGF may display two main functions: maintenance of 
endothelial cell survivals and vascular fenestrations in the healthy tissues.  
 
We also have found that anti-VEGF-induced thyroid vascular regression is 
completely reversible in a relatively short time (approximate two weeks) after 
discontinuation of anti-VEGF treatment. The vascular density and architecture return 
to nearly the same levels as the untreated animals after two weeks cessation of VEGF 
blockade. One possible explanation is that anti-VEGF drugs may increase VEGF 
expression levels in healthy tissues. 
 
Another clinical relevant finding is that anti-VEGF drugs completely suppressed the 
formation of endothelial fenestrations in thyroid vessels, which suggested that VEGF 
acts as a homeostatic factor for maintenance of vascular fenestrations in thyroid. It is 
well known that vascular fenestrations are crucial for maintenance of endocrine organ 
functions76,198. We have found the endocrine function of thyroid gland is impaired 
because there is low-level production of thyroxine after prolonged treatment with 
VEGF blockade.  
 
In paper IV, our findings reveal the functions of VEGF in maintenance of vascular 
homeostasis in various healthy tissues and organs. The anti-VEGF drugs induced 
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adverse effects in mice are in general concordance with clinically manifested adverse 
effects caused by these drugs in cancer patients. Thus, it is very important to 
understand the impacts of these anti-VEGF drugs in healthy tissues and organs in 
clinical treatment. 
 
 
 38 
6 CONCLUSIONS AND PERSPECTIVES 
 
Hem- and lymph- angiogenesis have gained more attentions recently. 
Hemangiogenesis, the process of sprouting new microvessels from the pre-existing 
blood vasculature, is known to promote tumor growth and metastasis. In addition to 
hemangiogenesis, various types of tumors often contain lymphatic vessels, which 
may facilitate lymphatic metastasis. Metastasis of malignant tumors to regional 
lymph nodes is one of the early signs of cancer spread in patients. In clinics, the 
extent of lymph node metastasis is a major determinant for the staging and the 
prognosis of cancer patients, which often guides therapeutic decisions. Since the 
recent discovery of the specific lymphatic vessel markers, the isolation of LECs, the 
establishment of lymphangiogenesis animal models, and the identification of the 
VEGF-C/VEGF-D-VEGFR-3 signaling pathway, great developments have been 
made at the molecular understanding of lymphangiogenesis.  
 
Understanding the biology of angiogenesis and lymphangiogenesis and how they are 
connected to tumor growth and tumor cells spread are fundamentally important in 
understanding the concept of hem- and lymph- angiogenesis in cancer metastasis. 
Although advances of imaging techniques allow detection of relative small sizes of 
tumors in cancer patients and in experimental animal models, the early onset of 
metastatic processes remains unknown. As more angiogenic and lymphangiogenic 
factors are discovered, the molecular interplay among these factors will probably 
become more complex. As for lymphangiogenesis, there has been lacking appropriate 
and powerful in vivo assay systems that allow us to study lymphangiogenesis 
quantitatively. 
 
In this thesis work, we have: 1) developed a novel zebrafish model to study the early 
steps of the metastatic cascade.  We took the advantage of the transparent nature of 
zebrafish embryos to visualize under normoxic and hypoxic conditions marked 
human or mouse tumor cell migration and invasion in association with tumor 
angiogenesis. We have found that tumor angiogenesis is essentially required for 
tumor cell invasion and dissemination. This study, for the first time, provide 
compelling evidence of tumor cell-tumor vessel interaction in promoting cancer cell 
dissemination to distal sites; 2) studied the interplay between FGF-2 and VEGF-C in 
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promoting lymphatic metastasis. In the tumor microenvironment, various angiogenic 
factors often co-exist and they often cross-communicate with different signaling 
pathways. Although the individual factor-transduced vertical signals via their specific 
receptors are relatively well studied, their horizontal interplay with other signaling 
systems remains poorly characterized. We show that FGF-2-triggered 
lymphangiogenic signaling pathways synergistically promote lymphangiogenesis 
with the VEGF-C/VEGFR-3 system, leading to synergistic lymphangiogenic effects 
in various in vivo models. This synergistic lymphangiogenic activity leads to 
accelerated lymphatic metastasis in sentinel lymph nodes; 3) developed a unique in 
vivo model to study lymphangiogenesis induced by various factors. We take the 
advantage of the avascular nature of the mouse corneal tissue and implant various 
growth factors/cytokines alone or in combinations to quantitatively study 
lymphangiogenesis and lymphatic structures; and 4) have also studied the impact of 
clinical available antiangiogenic drugs on healthy vasculatures and revealed potential 
sites for antiangiogenic drug-related side effects. 
 
In the field of cancer treatment, an extensive effort has been made to identify potent 
antiangiogenic agents, and some antiangiogenic drugs have already used in clinics or 
entered late stages of clinical trials. To anti-lymphangiogenesis treatment, maybe it is 
very important to develop anti-lymphangiogenesis therapeutic agents to block the 
pivotal signalling pathway of lymphangiogenesis that might be triggered by various 
growth factors. Understanding the molecular mechanisms of angiogenesis and 
lymphangiogenesis in cancers will help us to design therapeutic agents to target blood 
vessels and lymphatic vessels in cancer treatment. 
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